Verici Dx Regulatory News (VRCI)

Verici Dx plc

("Verici Dx" or the "Company") 

Result of AGM

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that at today's Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.

The results of the AGM will be made available on the Company's website: https://vericidx.com/

Enquiries:

About Verici Dx plc www.vericidx.com

Verici Dx is developing and commercialising tests to understand how a patient will and is responding to organ transplant, with an initial focus on kidney transplants. The body's own immune system poses a threat to a successful transplant or graft. Patients' immune systems differ in how they respond to the presence of the transplanted organ, characterising this response is called immune phenotyping. Our products and solutions are underpinned by extensive scientific research into the recipient's immune phenotype and how that impacts on acute rejection, chronic injury and ultimately failure of the transplant. These immuno-profile signatures also inform clinicians as to the optimal strategy for immunosuppressive and other therapies for the most successful treatment to ensure graft acceptance with the least amount of side effects.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.